

## Appendix D: Key to Acronyms

Updated: January 31, 2023

Reviewed: January 31, 2023

### Drug Name Abbreviations

| Acronym/Abbreviation | Full Name                         |
|----------------------|-----------------------------------|
| 3TC                  | lamivudine                        |
| ABC                  | abacavir                          |
| ATV                  | atazanavir                        |
| ATV/c                | atazanavir/cobicistat             |
| ATV/r                | atazanavir/ritonavir              |
| BIC                  | bictegravir                       |
| CAB                  | cabotegravir                      |
| CAB-LA               | cabotegravir-long acting          |
| COBI                 | cobicistat                        |
| d4T                  | stavudine                         |
| ddI                  | didanosine                        |
| DMPA                 | depot medroxyprogesterone acetate |
| DOR                  | doravirine                        |
| DRV                  | darunavir                         |
| DRV/c                | darunavir/cobicistat              |
| DRV/r                | darunavir/ritonavir               |
| DTG                  | dolutegravir                      |
| EFV                  | efavirenz                         |
| ENG                  | etonogestrel                      |
| ETR                  | etravirine                        |

|       |                               |
|-------|-------------------------------|
| EVG   | elvitegravir                  |
| EVG/c | elvitegravir/cobicistat       |
| FPV   | fosamprenavir                 |
| FPV/r | fosamprenavir/ritonavir       |
| FTC   | emtricitabine                 |
| FTR   | fostemsavir                   |
| IBA   | ibalizumab-uiyk               |
| IDV   | indinavir                     |
| IDV/r | indinavir/ritonavir           |
| INH   | isoniazid                     |
| LNG   | levonorgestrel                |
| LPV   | lopinavir                     |
| LPV/r | lopinavir/ritonavir           |
| MPA   | medroxyprogesterone acetate   |
| MVC   | maraviroc                     |
| NFV   | nelfinavir                    |
| NVP   | nevirapine                    |
| RAL   | raltegravir                   |
| RPV   | rilpivirine                   |
| RTV   | ritonavir                     |
| SQV   | saquinavir                    |
| SQV/r | saquinavir/ritonavir          |
| T20   | enfuvirtide                   |
| TAF   | tenofovir alafenamide         |
| TDF   | tenofovir disoproxil fumarate |

|        |                       |
|--------|-----------------------|
| TFV    | tenofovir             |
| TFV-DP | tenofovir diphosphate |
| TPV    | tipranavir            |
| TPV/r  | tipranavir/ritonavir  |
| ZDV    | zidovudine            |

## General Terms

| Acronym/Abbreviation | Full Name   |
|----------------------|---|
| AASLD                | Association for the Study of Liver Diseases         |
| ACOG                 | American College of Obstetricians and Gynecologists |
| ALT                  | alanine aminotransferase                            |
| anti-HBc             | anti-hepatitis B core antibody                      |
| anti-HBS             | hepatitis B surface antibody                        |
| aOR                  | adjusted odds ratio                                 |
| aHR                  | adjusted hazard ratio                               |
| aRR                  | adjusted risk ratio                                 |
| ART                  | antiretroviral therapy                              |
| ARV                  | antiretroviral                                      |
| AUC                  | area under the curve                                |
| AUC <sub>0-12h</sub> | area under the curve from 0 to 12 hours             |
| BMC                  | bone mineral content                                |
| BMD                  | bone mineral density                                |
| BMI                  | body mass index                                     |
| BHIVA                | British HIV Association                             |

|                     |  |
|---------------------|--|
| C <sub>12h</sub>    | concentration at 12 hours postdose         |
| C <sub>24h</sub>    | concentration at 24 hours postdose         |
| CAR                 | chimeric antigen receptor                  |
| CD4                 | CD4 T lymphocyte                           |
| CDC                 | Centers for Disease Control and Prevention |
| CI                  | confidence interval                        |
| C <sub>max</sub>    | maximum plasma concentration               |
| C <sub>min</sub>    | minimum plasma concentration               |
| C <sub>trough</sub> | trough concentration                       |
| CNS                 | central nervous system                     |
| CrCl                | creatinine clearance                       |
| CYP                 | cytochrome P450                            |
| CYP3A4              | cytochrome P450 3A4                        |
| DAA                 | direct-acting antiviral                    |
| DBS                 | dried blood spots                          |
| EC                  | enteric coated                             |
| EC <sub>90</sub>    | 90% maximal effective concentration        |
| ePPND               | enhanced Pre- and Postnatal Development    |
| FDA                 | U.S. Food and Drug Administration          |
| FDC                 | fixed-dose combination                     |
| GMC                 | geometric mean concentration               |
| gp                  | glycoprotein                               |
| HAV                 | hepatitis A virus                          |
| HBIG                | hepatitis B immune globulin                |
| HBcAb               | hepatitis B core antibody                  |

|                  |  |
|------------------|--|
| HBeAb            | hepatitis B e antibody                       |
| HBeAg            | hepatitis B e antigen                        |
| HbsAb            | hepatitis B surface antibody                 |
| HbsAg            | hepatitis B surface antigen                  |
| HBV              | hepatitis B virus                            |
| HCV              | hepatitis C virus                            |
| HCAZ             | head circumference–for–age z-scores          |
| HEU              | HIV exposed but uninfected                   |
| HD               | high dose                                    |
| HDP              | hypertensive disorders of pregnancy          |
| HUU              | HIV unexposed and uninfected                 |
| HR               | hazard ratio                                 |
| HRSA             | Health Resources and Services Administration |
| HSR              | hypersensitivity reaction                    |
| IC <sub>50</sub> | inhibitory concentration 50%                 |
| IGF              | insulin-like growth factor                   |
| IgG              | immunoglobulin G                             |
| IM               | intramuscular                                |
| INSTI            | integrase strand transfer inhibitor          |
| IPV              | intimate partner violence                    |
| IQR              | interquartile range                          |
| IDSA             | Infectious Diseases Society of America       |
| IUD              | intrauterine device                          |
| IUPC             | intrauterine pressure catheter               |
| IV               | intravenous/intravenously                    |

|           |  |
|-----------|--|
| LARC      | long-acting reversible contraceptive   |
| LAZ       | length-for-age z-scores  |
| LBW       | low birth weight   |
| mtDNA     | mitochondrial DNA  |
| NAT       | nucleic acid test  |
| NAT2      | N-acetyltransferase 2  |
| NHSS      | National HIV Surveillance System   |
| NICHD     | National Institute of Child Health and Human Development   |
| NIH       | National Institutes of Health  |
| NNRTI     | non-nucleoside reverse transcriptase inhibitor/non-nucleoside analogue reverse transcriptase inhibitor |
| nPEP      | non-occupational post-exposure prophylaxis   |
| NRTI      | nucleoside reverse transcriptase inhibitor/nucleoside analogue reverse transcriptase inhibitor         |
| NTD       | neural tube defect   |
| OARAC     | Office of AIDS Research Advisory Council   |
| OI        | opportunistic infection  |
| OR        | odds ratio   |
| The Panel | The Panel on Treatment of HIV in Pregnancy and Prevention of Perinatal Transmission                    |
| PBMC      | peripheral blood mononuclear cells   |
| PBPK      | physiologically based pharmacokinetic  |
| PJP       | <i>Pneumocystis jirovecii</i> pneumonia  |
| PCR       | polymerase chain reaction  |
| PI        | protease inhibitor   |

|              |   |
|--------------|---|
| PK           | pharmacokinetic                             |
| PO           | orally                                      |
| POC          | point of care                               |
| PPI          | proton pump inhibitor                       |
| PrEP         | pre-exposure prophylaxis                    |
| PTB          | preterm birth                               |
| RAM          | resistance-associated mutation              |
| RCT          | randomized controlled trial                 |
| RDS          | respiratory distress syndrome               |
| ROM          | rupture of membranes                        |
| RR           | relative risk                               |
| SGA          | small for gestational age                   |
| sPTB         | spontaneous preterm birth                   |
| STI          | sexually transmitted infection              |
| $t_{1/2app}$ | terminal-phase half-life                    |
| TB           | tuberculosis                                |
| Tdap         | tetanus, diphtheria and pertussis           |
| TDM          | therapeutic drug monitoring                 |
| UGT          | uridine diphosphate glucuronosyltransferase |
| vPTB         | very preterm birth                          |
| VL           | viral load                                  |
| vSGA         | very small for gestational age              |
| WAZ          | weight-for-age z-scores                     |
| WHO          | World Health Organization                   |

## Study and Trial Names

| Acronym/Abbreviation | Full Name  |
|----------------------|--|
| BAN                  | Breastfeeding, Antiretrovirals, and Nutrition                    |
| DolPHIN 2            | Dolutegravir in Pregnant HIV Women and Their Neonates            |
| EUROCAT              | European Surveillance of Congenital Anomalies and Twins          |
| HPTN                 | HIV Prevention Trials Network                                    |
| IMPAACT              | International Maternal Pediatric Adolescent AIDS Clinical Trials |
| MOTIVATE             | Mother–Infant Visit Adherence and Treatment Engagement           |
| PACTG                | Pediatric AIDS Clinical Trials Group                             |
| PARTNER              | Partners of People on ART-A New Evaluation of the Risks          |
| PHACS                | Pediatric HIV/AIDS Cohort Study                                  |
| PROMISE              | Promoting Maternal and Infant Survival Everywhere                |
| SMARTT               | Surveillance and Monitoring for ART Toxicities                   |